ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

(NASDAQ:PMN), Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused […]

McFarlane Initiates Environmental Baseline Study Work for Juby

(CNSX:MLM.CN),(OTC US:MLMLF),(OtherOTC:MLMLF), TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company“) (CSE: MLM, OTC: MLMLF) a leading Canadian gold exploration company focused on advancing its flagship Juby Gold Project, located approximately 15 kilometers west from Gowganda, Ontario and approximately 90 kilometers west from Temiskaming Shores, Ontario is pleased to

Beyond Oil Reports Financial Results for the Third Quarter of 2025

(TSX:BOIL),(OTC US:BEOLF),(Other OTC:BEOLF),(Boerse Frankfurt – Freiverkehr:UH9),(Boerse Frankfurt – Freiverkehr:UH9.F), Compared to the Previous Corresponding Quarterly Period, Revenue Increased 779% (US$133K to US$1.2M); Increase in Gross Profit; Strong Cash Position Growth Trajectory Remains Strong First Tranche of Previously Shareholder Approved Milestone Shares to be Issued After Reaching US$3M Revenue Milestone VANCOUVER, British Columbia, Dec. 01, 2025

Morien Maiden Drill Program Underway at Lazy Head Aggregate Project

(TSX-V:MOX), HALIFAX, Nova Scotia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Morien Resources Corp. (“Morien” or the “Company”) (TSX-V: MOX) is pleased to announce that it has commenced a maiden drill program at the Lazy Head Aggregate Project (“Lazy Head” or the “Project”) in the Municipality District of Guysborough (the “MODG”), Nova Scotia (the “Drill Program”

Pulse Oil Corp. Announces Amendments to Facility Agreements and Updates EOR Progress

(TSX-V:PUL), VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Pulse Oil Corp. (“Pulse” or the “Company“) (TSXV: PUL) is pleased to announce that Pulse has entered into amending agreements to the two loan Facility Agreements (the “Facility Agreements“) with two arms-length parties to the Company (the “Lenders“) announced in the Company's press release of

FuelCell Energy Secures $25M in Repeat EXIM Financing for Gyeonggi Green Energy Fuel Cell Project in Korea

(NasdaqGM:FCEL), DANBURY, Conn., Dec. 01, 2025 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) has announced today that it has closed a new round of debt financing with the Export-Import Bank of the United States (EXIM), marking a continued commitment from EXIM to support the Company's growth ambitions to deliver utility grade power in international

Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – TLX

(NASDAQ:TLX), LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Altimmune Announces CEO Transition and Succession Plan

(NasdaqGM:ALT), Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

(NASDAQ:MDCX), PHILADELPHIA, Dec. 01, 2025 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Carolyn Bonner, currently President of the Company, has also been appointed Chief Financial Officer, effective

Hypercharge Reports Second Quarter Fiscal 2026 Results

(TSX-V – NEX Board:HC),(OTC US:HCNWF),(OtherOTC:HCNWF), Recognized Revenue of $3.7 Million, Up $2.3 Million Year-Over-Year Gross Profit of $0.9 Million, Up $0.4 Million Year-Over-Year Net and Comprehensive Loss Reduced by 63% Year-Over-Year Delivered 319 New Charging Ports, Including 48 DC Fast Charging Ports VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV:

Scroll to Top